IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2024-05, Vol.143 (18), p.1873-1877
Main Authors: Hong, Lih En, Wechalekar, Mihir D., Kutyna, Monika, Small, Annabelle, Lim, Kelly, Thompson-Peach, Chloe, Li, Joule J., Chhetri, Rakchha, Scott, Hamish S., Brown, Anna, Hahn, Christopher N., Yeung, David T., Sajid, Salvia, Robinson, Nirmal, Thomas, Ranjeny, Branford, Susan, D’Andrea, Richard J., Samaraweera, Saumya E., Patnaik, Mrinal, Proudman, Susanna, Thomas, Daniel, Kok, Chung Hoow, Shah, Mithun V., Hiwase, Devendra K.
Format: Article
Language:English
Subjects:
Aged
Arthritis, Rheumatoid - genetics
Arthritis, Rheumatoid - immunology
Female
Humans
Immunity, Innate
Isocitrate Dehydrogenase - genetics
Male
Middle Aged
Mutation
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation of IDH inhibitors as therapeutics for seronegative IDH-mutated RA.
ISSN:0006-4971
1528-0020
1528-0020
DOI:10.1182/blood.2023023593